X4 Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results significantly exceeded consensus expectations on the top and bottom lines, driven by a massive revenue beat of $8.8M vs. $2.4M expected. The variance was primarily due to a $5.5M regulatory milestone from the Norgine partnership following EU approval of XOLREMDI. Net loss narrowed to -$0.13 per share, outperforming the -$0.18 consensus, supported by strategic restructuring that lowered R&D and G&A expenses. Management confirmed a cash runway of at least 12 months with $208M in liquidity, while shifting focus to the pivotal Phase 3 4WARD trial update expected in Q3.